Zealand Pharma completed the acquisition of Valeritas for $23m.

Zealand Pharma, a Denmark-based biotechnology company, completed the acquisition of Valeritas, a medical technology company, for $23m. “We are thrilled to welcome more US employees to the Zealand team, along with the opportunity to offer the V-Go® wearable insulin delivery device to help people manage their diabetes. The acquisition transforms Zealand into a fully-integrated biotech company with an established footprint in the U.S. diabetes market. We will work quickly to optimize our operations and ensure readiness for the potential launch of the dasiglucagon HypoPal® rescue pen in 2021,” Emmanuel Dulac, Zealand Pharma President and Chief Executive Officer.